| pubmed-article:14752778 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:14752778 | lifeskim:mentions | umls-concept:C0312740 | lld:lifeskim |
| pubmed-article:14752778 | lifeskim:mentions | umls-concept:C1519477 | lld:lifeskim |
| pubmed-article:14752778 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:14752778 | lifeskim:mentions | umls-concept:C0281604 | lld:lifeskim |
| pubmed-article:14752778 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
| pubmed-article:14752778 | lifeskim:mentions | umls-concept:C1515895 | lld:lifeskim |
| pubmed-article:14752778 | lifeskim:mentions | umls-concept:C2348628 | lld:lifeskim |
| pubmed-article:14752778 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:14752778 | pubmed:dateCreated | 2004-1-30 | lld:pubmed |
| pubmed-article:14752778 | pubmed:abstractText | The effect of allogeneic versus syngeneic killer cells derived from normal or severe combined immunodeficiency disease (SCID) mice was evaluated for induction of antitumor reaction in a murine model of mammary carcinoma. Tumor cells of H-2d origin were injected intravenously into H-2(d/b) mice 24 hours after total body irradiation (4 Gy). On the following day, lymphokine-activated killer (LAK) splenocytes, derived from either minor (H-2d) or major (H-2b) histocompatibility complex (MHC)-mismatched parental normal mice or MHC (H-2b)-mismatched SCID mice, were given intravenously. LAK cells of H-2d normal or SCID mice, syngeneic to the tumor, were inoculated in parallel. The results show that LAK cells derived from minor histocompatibility complex-mismatched or MHC-mismatched parental normal mice improved the probability of tumor-free survival as compared with LAK cells syngeneic to the tumor cells, but they aggravated the severity of graft-versus-host disease. SCID splenocytes serving as a source of natural killer (NK) cells were expanded and activated in vitro by rIL-2 to obtain a sufficient number of DX5+ CD3- CD8- NK cells (SCID-LAK). H-2b SCID-LAK cells did not cause graft-versus-host disease and significantly delayed tumor growth compared with syngeneic H-2d SCID-LAK cells, as indicated by tumor colony assays in vitro and adoptive transfer experiments. However, the graft-versus-tumor effect was not long lasting, and treated mice finally died of tumor. Our results show an advantage of allogeneic over syngeneic cell therapy for achieving a graft-versus-tumor effect by rIL-2-activated T cells and NK cells. Periodic repetition of NK treatments may be required to achieve more durable antitumor effects. | lld:pubmed |
| pubmed-article:14752778 | pubmed:language | eng | lld:pubmed |
| pubmed-article:14752778 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14752778 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:14752778 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:14752778 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:14752778 | pubmed:issn | 1083-8791 | lld:pubmed |
| pubmed-article:14752778 | pubmed:author | pubmed-author:SlavinShimonS | lld:pubmed |
| pubmed-article:14752778 | pubmed:author | pubmed-author:MoreckiShosha... | lld:pubmed |
| pubmed-article:14752778 | pubmed:author | pubmed-author:YacovlevElena... | lld:pubmed |
| pubmed-article:14752778 | pubmed:author | pubmed-author:GelfandYaelY | lld:pubmed |
| pubmed-article:14752778 | pubmed:author | pubmed-author:VilenskyAnnaA | lld:pubmed |
| pubmed-article:14752778 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:14752778 | pubmed:volume | 10 | lld:pubmed |
| pubmed-article:14752778 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:14752778 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:14752778 | pubmed:pagination | 40-8 | lld:pubmed |
| pubmed-article:14752778 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:14752778 | pubmed:meshHeading | pubmed-meshheading:14752778... | lld:pubmed |
| pubmed-article:14752778 | pubmed:meshHeading | pubmed-meshheading:14752778... | lld:pubmed |
| pubmed-article:14752778 | pubmed:meshHeading | pubmed-meshheading:14752778... | lld:pubmed |
| pubmed-article:14752778 | pubmed:meshHeading | pubmed-meshheading:14752778... | lld:pubmed |
| pubmed-article:14752778 | pubmed:meshHeading | pubmed-meshheading:14752778... | lld:pubmed |
| pubmed-article:14752778 | pubmed:meshHeading | pubmed-meshheading:14752778... | lld:pubmed |
| pubmed-article:14752778 | pubmed:meshHeading | pubmed-meshheading:14752778... | lld:pubmed |
| pubmed-article:14752778 | pubmed:meshHeading | pubmed-meshheading:14752778... | lld:pubmed |
| pubmed-article:14752778 | pubmed:meshHeading | pubmed-meshheading:14752778... | lld:pubmed |
| pubmed-article:14752778 | pubmed:meshHeading | pubmed-meshheading:14752778... | lld:pubmed |
| pubmed-article:14752778 | pubmed:meshHeading | pubmed-meshheading:14752778... | lld:pubmed |
| pubmed-article:14752778 | pubmed:meshHeading | pubmed-meshheading:14752778... | lld:pubmed |
| pubmed-article:14752778 | pubmed:meshHeading | pubmed-meshheading:14752778... | lld:pubmed |
| pubmed-article:14752778 | pubmed:meshHeading | pubmed-meshheading:14752778... | lld:pubmed |
| pubmed-article:14752778 | pubmed:meshHeading | pubmed-meshheading:14752778... | lld:pubmed |
| pubmed-article:14752778 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:14752778 | pubmed:articleTitle | Allogeneic versus syngeneic killer splenocytes as effector cells for the induction of graft-versus-tumor effect. | lld:pubmed |
| pubmed-article:14752778 | pubmed:affiliation | Department of Bone Marrow Transplantation & Cancer Immunotherapy, Cell Therapy & Transplantation Research Center, Hadassah University Hospital, Jerusalem, Israel. morecki@hadassah.org.il | lld:pubmed |
| pubmed-article:14752778 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:14752778 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:14752778 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
